217 reports of this reaction
4.7% of all PROPAFENONE HYDROCHLORIDE reports
#1 most reported adverse reaction
ATRIAL FIBRILLATION is the #1 most commonly reported adverse reaction for PROPAFENONE HYDROCHLORIDE, manufactured by Actavis Pharma, Inc.. There are 217 FDA adverse event reports linking PROPAFENONE HYDROCHLORIDE to ATRIAL FIBRILLATION. This represents approximately 4.7% of all 4,618 adverse event reports for this drug.
Patients taking PROPAFENONE HYDROCHLORIDE who experience atrial fibrillation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ATRIAL FIBRILLATION is moderately reported among PROPAFENONE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to atrial fibrillation, the following adverse reactions have been reported for PROPAFENONE HYDROCHLORIDE:
The following drugs have also been linked to atrial fibrillation in FDA adverse event reports:
ATRIAL FIBRILLATION has been reported as an adverse event in 217 FDA reports for PROPAFENONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ATRIAL FIBRILLATION accounts for approximately 4.7% of all adverse event reports for PROPAFENONE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience atrial fibrillation while taking PROPAFENONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.